[{"id":"e41df1b0-a381-4409-acf3-86d752328c66","acronym":"","url":"https://clinicaltrials.gov/study/NCT07472933","created_at":"2026-03-28T01:36:46.537Z","updated_at":"2026-03-28T01:36:46.537Z","phase":"Phase 2","brief_title":"Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies","source_id_and_acronym":"NCT07472933","lead_sponsor":"West China Hospital","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 02/29/2028","primary_completion_date":" 02/29/2028","study_txt":" Completion: 02/29/2028","study_completion_date":" 02/29/2028","last_update_posted":"2026-03-18"},{"id":"d56691d6-631f-4daa-9d9c-1b3527ec47af","acronym":"SAFE ESO","url":"https://clinicaltrials.gov/study/NCT07205731","created_at":"2025-10-11T01:29:40.189Z","updated_at":"2025-10-11T01:29:40.189Z","phase":"Phase 2","brief_title":"Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma","source_id_and_acronym":"NCT07205731 - SAFE ESO","lead_sponsor":"University Hospital, Clermont-Ferrand","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 10/01/2029","primary_completion_date":" 10/01/2029","study_txt":" Completion: 10/01/2030","study_completion_date":" 10/01/2030","last_update_posted":"2025-10-03"},{"id":"ab44ad05-9bd9-4db7-9ebb-ab1b8496e06f","acronym":"","url":"https://clinicaltrials.gov/study/NCT07190027","created_at":"2025-09-27T08:39:53.097Z","updated_at":"2025-09-27T08:39:53.097Z","phase":"Phase 1/2","brief_title":"Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial","source_id_and_acronym":"NCT07190027","lead_sponsor":"First Affiliated Hospital of Wenzhou Medical University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 246","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2025-09-24"},{"id":"7ee22b9c-eea6-45ba-bdc2-0adfd9a6a3e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07174908","created_at":"2025-09-20T07:06:19.138Z","updated_at":"2025-09-20T07:06:19.138Z","phase":"Phase 3","brief_title":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","source_id_and_acronym":"NCT07174908","lead_sponsor":"InxMed (Shanghai) Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • pemetrexed • Anfangning (garsorasib) • ifebemtinib (IN10018)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2025-09-16"},{"id":"dacc9da3-7f50-4fcd-b6ab-f82afa578e33","acronym":"","url":"https://clinicaltrials.gov/study/NCT07025850","created_at":"2025-06-21T13:17:03.504Z","updated_at":"2025-06-21T13:17:03.504Z","phase":"Phase 1/2","brief_title":"Digoxin Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients","source_id_and_acronym":"NCT07025850","lead_sponsor":"Fudan University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-06-18"},{"id":"f43e758f-4bc3-4256-ae14-899721a6e9b8","acronym":"GALENT-BT","url":"https://clinicaltrials.gov/study/NCT06963060","created_at":"2025-09-07T01:31:36.203Z","updated_at":"2025-09-07T01:31:36.203Z","phase":"Phase 2","brief_title":"Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)","source_id_and_acronym":"NCT06963060 - GALENT-BT","lead_sponsor":"Wei Gong","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 44","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-05-08"},{"id":"ddb28914-edb2-4733-8bbd-06431d3d7e9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06856837","created_at":"2025-09-07T01:48:45.276Z","updated_at":"2025-09-07T01:48:45.276Z","phase":"Phase 2","brief_title":"- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases","source_id_and_acronym":"NCT06856837","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-03-04"},{"id":"ec39bba5-c725-4310-a7b9-db843f8fcd99","acronym":"AdvanTIG-206","url":"https://clinicaltrials.gov/study/NCT04948697","created_at":"2021-07-02T12:52:38.466Z","updated_at":"2025-02-25T12:28:13.406Z","phase":"Phase 2","brief_title":"A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC","source_id_and_acronym":"NCT04948697 - AdvanTIG-206","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)"],"overall_status":"Completed","enrollment":" Enrollment 94","initiation":"Initiation: 08/20/2021","start_date":" 08/20/2021","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2025-02-24"},{"id":"308e274e-e2f7-4972-a5fd-9ed7015b2fc2","acronym":"HERIZON-GEA-01","url":"https://clinicaltrials.gov/study/NCT05152147","created_at":"2021-12-09T18:00:29.644Z","updated_at":"2025-02-25T14:02:38.513Z","phase":"Phase 3","brief_title":"A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","source_id_and_acronym":"NCT05152147 - HERIZON-GEA-01","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • cisplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • Ziihera (zanidatamab-hrii)"],"overall_status":"Recruiting","enrollment":" Enrollment 918","initiation":"Initiation: 12/02/2021","start_date":" 12/02/2021","primary_txt":" Primary completion: 05/15/2025","primary_completion_date":" 05/15/2025","study_txt":" Completion: 05/15/2026","study_completion_date":" 05/15/2026","last_update_posted":"2025-02-19"},{"id":"ebbc984b-827d-44a5-9985-f8960dd46a9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06835179","created_at":"2025-02-25T14:06:14.436Z","updated_at":"2025-02-25T14:06:14.436Z","phase":"Phase 2","brief_title":"SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.","source_id_and_acronym":"NCT06835179","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-02-19"},{"id":"53c57014-eed8-45c6-afa4-43da3ec376e4","acronym":"BGB-A317-214","url":"https://clinicaltrials.gov/study/NCT05116085","created_at":"2021-11-10T14:13:08.209Z","updated_at":"2025-02-25T14:08:28.217Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer","source_id_and_acronym":"NCT05116085 - BGB-A317-214","lead_sponsor":"BeiGene","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 01/26/2022","start_date":" 01/26/2022","primary_txt":" Primary completion: 09/26/2023","primary_completion_date":" 09/26/2023","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-18"},{"id":"03ad2ae1-62eb-4ee9-9973-fa23d5f2634d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05904496","created_at":"2023-06-15T17:08:23.801Z","updated_at":"2025-02-25T14:18:02.487Z","phase":"Phase 1","brief_title":"A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05904496","lead_sponsor":"BeiGene","biomarkers":" TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • BGB-30813"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/19/2023","start_date":" 07/19/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-17"},{"id":"acb735f2-e0d3-48ef-9323-330de9633b97","acronym":"BGB-900-102","url":"https://clinicaltrials.gov/study/NCT03744468","created_at":"2021-01-18T18:20:22.768Z","updated_at":"2025-02-25T14:40:03.995Z","phase":"Phase 1/2","brief_title":"Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors","source_id_and_acronym":"NCT03744468 - BGB-900-102","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007) • surzebiclimab (BGB-A425)"],"overall_status":"Completed","enrollment":" Enrollment 114","initiation":"Initiation: 11/13/2018","start_date":" 11/13/2018","primary_txt":" Primary completion: 02/06/2025","primary_completion_date":" 02/06/2025","study_txt":" Completion: 02/06/2025","study_completion_date":" 02/06/2025","last_update_posted":"2025-02-14"},{"id":"d1c6f091-2d7d-4e24-bd1c-40f7dd6031e6","acronym":"RATIONALE 305","url":"https://clinicaltrials.gov/study/NCT03777657","created_at":"2024-05-12T00:59:46.180Z","updated_at":"2025-02-25T14:40:05.546Z","phase":"Phase 3","brief_title":"Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma","source_id_and_acronym":"NCT03777657 - RATIONALE 305","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin"],"overall_status":"Completed","enrollment":" Enrollment 997","initiation":"Initiation: 12/13/2018","start_date":" 12/13/2018","primary_txt":" Primary completion: 02/28/2023","primary_completion_date":" 02/28/2023","study_txt":" Completion: 08/27/2024","study_completion_date":" 08/27/2024","last_update_posted":"2025-02-14"},{"id":"9afa710d-568f-4738-a48f-bfb574489fff","acronym":"HFB-200603-01","url":"https://clinicaltrials.gov/study/NCT05789069","created_at":"2023-03-29T14:03:20.087Z","updated_at":"2025-02-25T15:13:24.022Z","phase":"Phase 1","brief_title":"A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05789069 - HFB-200603-01","lead_sponsor":"HiFiBiO Therapeutics","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • HFB200603"],"overall_status":"Recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 05/09/2023","start_date":" 05/09/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-13"},{"id":"5e06588b-c110-45fd-a169-3b979969f583","acronym":"","url":"https://clinicaltrials.gov/study/NCT05299476","created_at":"2022-03-29T13:52:56.012Z","updated_at":"2025-02-25T15:35:32.829Z","phase":"Phase 2","brief_title":"CAPOX + Bevacizumab + Tirelizumab Treating PDL1 CPS \u003c 5 GEA","source_id_and_acronym":"NCT05299476","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/16/2022","start_date":" 04/16/2022","primary_txt":" Primary completion: 01/20/2025","primary_completion_date":" 01/20/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-11"},{"id":"58376e7f-576d-46f9-b0f9-c359b7e3ff5d","acronym":"RATIONALE-303","url":"https://clinicaltrials.gov/study/NCT03358875","created_at":"2021-01-17T17:34:22.841Z","updated_at":"2025-02-25T15:25:42.091Z","phase":"Phase 3","brief_title":"Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT03358875 - RATIONALE-303","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Completed","enrollment":" Enrollment 805","initiation":"Initiation: 11/30/2017","start_date":" 11/30/2017","primary_txt":" Primary completion: 07/15/2021","primary_completion_date":" 07/15/2021","study_txt":" Completion: 01/18/2024","study_completion_date":" 01/18/2024","last_update_posted":"2025-02-10"},{"id":"a46eecea-cdfb-4325-ac71-c96ea8e37386","acronym":"","url":"https://clinicaltrials.gov/study/NCT05823311","created_at":"2023-04-21T15:04:25.336Z","updated_at":"2025-02-25T15:20:26.716Z","phase":"Phase 3","brief_title":"Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma","source_id_and_acronym":"NCT05823311","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-10"},{"id":"f87d079d-5408-46e1-abc8-978710f92fcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05532059","created_at":"2022-09-08T13:55:00.765Z","updated_at":"2025-02-25T15:27:37.097Z","phase":"Phase 2","brief_title":"Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma","source_id_and_acronym":"NCT05532059","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/31/2022","start_date":" 01/31/2022","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2025-02-10"},{"id":"b85874df-7e06-4405-a134-b832b090826f","acronym":"RCTS","url":"https://clinicaltrials.gov/study/NCT05586061","created_at":"2022-10-19T13:56:28.812Z","updated_at":"2025-02-25T16:33:09.486Z","phase":"Phase 2","brief_title":"First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer","source_id_and_acronym":"NCT05586061 - RCTS","lead_sponsor":"Qilu Hospital of Shandong University","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 02/10/2023","start_date":" 02/10/2023","primary_txt":" Primary completion: 12/29/2024","primary_completion_date":" 12/29/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-07"},{"id":"bd048b8e-a7db-4137-9356-c4eef9e3d0d4","acronym":"BGB-A317-A445-101","url":"https://clinicaltrials.gov/study/NCT04215978","created_at":"2022-08-30T23:00:45.831Z","updated_at":"2025-02-25T16:37:41.515Z","phase":"Phase 2","brief_title":"Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT04215978 - BGB-A317-A445-101","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • BGB-A445"],"overall_status":"Completed","enrollment":" Enrollment 204","initiation":"Initiation: 01/30/2020","start_date":" 01/30/2020","primary_txt":" Primary completion: 01/24/2025","primary_completion_date":" 01/24/2025","study_txt":" Completion: 01/24/2025","study_completion_date":" 01/24/2025","last_update_posted":"2025-02-06"},{"id":"d0aa4f16-7694-44b7-8f9e-f75259b43f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT05544929","created_at":"2022-09-19T14:56:40.664Z","updated_at":"2025-02-25T16:39:18.617Z","phase":"Phase 1","brief_title":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","source_id_and_acronym":"NCT05544929","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • KFA115"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 02/20/2026","primary_completion_date":" 02/20/2026","study_txt":" Completion: 02/20/2026","study_completion_date":" 02/20/2026","last_update_posted":"2025-02-06"},{"id":"b2f66c0e-6c9b-4463-9368-140116887239","acronym":"ACROPOLI","url":"https://clinicaltrials.gov/study/NCT04802876","created_at":"2021-03-17T15:57:42.481Z","updated_at":"2025-02-25T15:44:25.480Z","phase":"Phase 2","brief_title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","source_id_and_acronym":"NCT04802876 - ACROPOLI","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 04/12/2021","start_date":" 04/12/2021","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-04"},{"id":"ac22c3c9-66ab-4000-be70-b84ca8b1533a","acronym":"BGB-LC-201","url":"https://clinicaltrials.gov/study/NCT05635708","created_at":"2022-12-02T15:56:38.256Z","updated_at":"2025-02-25T16:18:24.125Z","phase":"Phase 2","brief_title":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05635708 - BGB-LC-201","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed • BGB-15025 • BGB-A445 • alcestobart (LBL-007)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 03/07/2023","start_date":" 03/07/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-01-31"}]